Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials
NCT ID: NCT01799356
Last Updated: 2013-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1303 participants
INTERVENTIONAL
2010-06-30
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
moxifloxacin Group
Treatment at uPID with moxifloxacin
Moxifloxacin
daily 400 mg moksifloksasin
Ofloxacin Group
Treatment at uPID with Ofloxacin plus metronidazole
Ofloxacin
daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
Metronidazole
daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moxifloxacin
daily 400 mg moksifloksasin
Ofloxacin
daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
Metronidazole
daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients age are between 14 with 45
3. Pelvic tenderness and vaginal discharge
Exclusion Criteria
2. Tubo-ovarian abscess and complicated PID
3. Hıstory of antibiotics treatment
4. Other pelvic pain causes
5. Endometriosis
6. Delivery,abortion and surgery within last months
14 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul Bakirkoy Maternity and Children Diseases Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Osman Aşıcıoğlu
Istanbul Sisli Etfal Training Research Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kemal Gungorduk, md
Role: STUDY_CHAIR
T.C.S.B. Kanıni Sultan Suleyman Training Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
T.C.S.B. İstanbul Training Research Hospital
Samatya, Fatih, Turkey (Türkiye)
T.C.S.B. Kanuni Sultan Suleyman Training Hospital
Istanbul, Kucukcekmece, Turkey (Türkiye)
T.C.S.B Mardin Women and Children Hospital
Mardin, Mardin, Turkey (Türkiye)
T.C.S.B. Şişli Etfal Training Research Hospital
Şişli, Şişli, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Judlin P, Liao Q, Liu Z, Reimnitz P, Hampel B, Arvis P. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG. 2010 Nov;117(12):1475-84. doi: 10.1111/j.1471-0528.2010.02687.x. Epub 2010 Aug 18.
Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS. 2010 Mar;21(3):195-7. doi: 10.1258/ijsa.2009.009374.
Savaris RF, Fuhrich DG, Maissiat J, Duarte RV, Ross J. Antibiotic therapy for pelvic inflammatory disease. Cochrane Database Syst Rev. 2020 Aug 20;8(8):CD010285. doi: 10.1002/14651858.CD010285.pub3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
treatment
Identifier Type: OTHER
Identifier Source: secondary_id
treatment uPID
Identifier Type: OTHER
Identifier Source: secondary_id
Asicioglu03
Identifier Type: -
Identifier Source: org_study_id